Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment
Status:
Recruiting
Trial end date:
2022-05-02
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the effect of hepatic impairment on the
systemic pharmacokinetics, safety, and tolerability of icenticaftor in participants with
varying degrees of hepatic impairment.